Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: breast + cancer + 0.26  Related to the article below (Last Update: 8/5/2008)

GTx, Inc. Reports Second Quarter 2008 Financial Results
StreetInsider.com (subscription), MI -
Net sales of FARESTON(R) (toremifene citrate) 60 mg, marketed for the treatment of metastatic breast cancer in postmenopausal women, were $274000 and ...GTXI
Source: Google News

The effect of raloxifene on risk of breast cancer in postmenopausal women -
SR Cummings, S Eckert, KA Krueger, D Grady, TJ … - feedback, 2005 - biomedcentral.com
... risk of ER positive invasive breast cancer (RR, 0.10; 95% CI, 0.04-0.24) but did
not have the same effect on ER negative disease (RR, 0.88; 95% CI, 0.26-3.00). ...

[CITATION] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer -
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, … - New England Journal of Medicine, 2004 - Mass Med Soc
... 2.81) Poorly differentiated <0.001 3.34 (1.79?6.26) HER2 amplification 0.06 0.51
(0.26?1.02) Estrogen ... multigene assay to predict recurrence of breast cancer ...

Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in … -
M Maliepaard, GL Scheffer, IF Faneyte, MA van … - Cancer Research, 2001 - AACR
... and breast correlated with low BCRP/PBGD ratios (0.26 and 0.85 ... 3-amino-9-ethylcarbazole;
ECL, enhanced chemiluminescence; BCRP, Breast Cancer Resistance Protein ...

BREAST-CANCER RISK FOLLOWING LONG-TERM OESTROGEN-AND OESTROGEN-PROGESTIN-REPLACEMENT THERAPY -
C Magnusson, JA Baron, N Correia, R Bergstrom, HO … - Int. J. Cancer, 1999 - doi.wiley.com
... In this population-based case-control study, 3,345 women aged 50 to 74 years with
invasive breast cancer (84% of all eligible) and 3,454 controls of similar ...

Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1 … -
U Kumar, SI Grigorakis, HL Watt, R Sasi, L Snell, … - Breast Cancer Research and Treatment, 2005 - Springer
... of expression of individual SSTRs in tumors (eg, breast cancer). ... histological profile
in primary ductal NOS breast tumor ... 10800 0.12 0.26 0.29 0.03 0.22 6 60 40 ...

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal … -
RT Chlebowski, SL Hendrix, RD Langer, ML Stefanick … - JAMA, 2003 - geisingermedicalcenter.com
... on Breast Cancer and Mammography ... These results suggest estrogen plus progestin may
stimulate breast can- cer growth and hinder breast cancer diagnosis. JAMA. ...

… Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer -
CK Osborne, V Bardou, TA Hopp, GC Chamness, SG … - jnci, 2003 - jnci.oxfordjournals.org
... An SDS extract of the T47D human breast cancer cell line was used as a ... Normalized
band intensity, using the MCF-7 reference standard, ranged from 0.26 to 5.7 ...

Physical Activity and Survival After Breast Cancer Diagnosis -
MD Holmes, WY Chen, D Feskanich, CH Kroenke, GA … - JAMA, 2005 - Am Med Assoc
... and compared with women who engaged in less than 3 MET-hours per week of physical
activity, the RR of death from breast cancer was 0.63 (95% CI, 0.26-1.52) for ...

The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Breast Cancer 1 -
CA Haiman, SE Hankinson, D Spiegelman, GA Colditz, … - Cancer Research, 1999 - AACR
... Women with the A2 allele were not at an increased risk of breast cancer; the controls
(64.9%) and cases (61.6%) carried at least one A2 allele (P = 0.26). ...

Vegetables, Fruits, and Related Nutrients and Risk of Breast Cancer: A Case-Control Study in Uruguay -
A Ronco, E De Stefani, P Boffetta, H Deneo- … - Nutrition and Cancer, 1999 - Lawrence Earlbaum
... shown in Table 2. Total vegetable intake was inversely associated with risk of breast
cancer [OR = 0.41, 95% confidence interval (CI) = 0.26?0.65], whereas ...

Source: Google Scholar

Breast cancer survival longer with Taxotere: study

Last Updated: 2007-12-13 16:47:50 -0400 (Reuters Health)

By Martha Kerr

NEW YORK (Reuters Health) - The long-term findings of a large, multicenter study show that breast cancer survival is significantly improved and side effects are significantly less severe with Taxotere (also called docetaxel) than with Adriamycin (also called doxorubicin).

The findings "have the potential to be practice-changing," principal investigator Dr. Stephen Jones of the US Oncology Medical Center in Houston, Texas told Reuters Health.

Jones presented his group's findings today, the opening day of the San Antonio Breast Cancer Symposium.

The trial involved 1,016 women with breast cancer who had complete surgical excision of the primary tumor. In approximately half of the women, the cancer had not spread to the lymph nodes.

Between June 1997 and December 1999, women were randomly assigned to four cycles of Taxotere plus cyclophosphamide or four cycles of standard therapy with Adriamycin plus cyclophosphamide, administered by infusion every 3 weeks as adjuvant or "add-on" chemotherapy.

Radiation therapy and tamoxifen were given after completion of chemotherapy for patients with so-called hormone receptor-positive disease.

There was a significant survival advantage with Taxotere, Jones announced. "Stated another way, these women had a 31 percent lower risk of dying during follow-up" than those receiving the gold standard, he said.

Taxotere has the "added advantage of fewer and less severe adverse effects," Jones said. Adriamycin has a significant risk of cardiac toxicity, especially in older women. It is also associated with some types of leukemia, he explained.

Taxotere does have some side effects, however. It can still cause nausea and vomiting and hair loss, "but this is not as severe as with (Adriamycin)," the Houston investigator said. "We have shown that a lot of women with early breast cancers don't have to receive Adriamycin-based regimens."

Taxotere plus cyclophosphamide "would appear to be the new standard of care for node-negative women and for those with involvement of up to three local nodes...We don't have a lot of information on women with more than four positive nodes," Jones acknowledged.

"Now that we can see this survival advantage, we can incorporate this regimen into other treatment regimens with other agents," Jones added.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.